Literature DB >> 9607202

Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats.

U Schwarz1, K Amann, S R Orth, A Simonaviciene, S Wessels, E Ritz.   

Abstract

In the past, there has been considerable concern that treatment with active vitamin D might accelerate progression independent of hypercalcemia and hypercalcuria. Nevertheless, 1,25(OH)2D3 has known antiproliferative properties and has also been shown to inhibit renal growth. Since glomerular growth is a permissive factor for the development of glomerulosclerosis, we reasoned that 1,25(OH)2D3 might even attenuate progression. To test this working hypothesis we performed two experiments of 8 and 16 weeks duration, respectively, to compare subtotally nephrectomized (SNX) rats treated with ethanol and SNX treated with 1,25(OH)2D3. Control animals were sham operated and pair-fed with SNX animals. 1,25(OH)2D3 (3 ng/100 g body wt/day) was administered by osmotic minipump. 1,25(OH)2D3 had no significant effect on systolic blood pressure and only a transient effect on weight gain. SNX reduced the number of glomeruli (left kidney) from an average of 3.3 x 10(4) to 1.2 x 10(4) per kidney. Mean glomerular volume was 3.87 +/- 0.71 x 10(6) microns 3 in sham operated animals and significantly (P < 0.05) higher (10.1 +/- 1.75 x 10(6) microns 3) in untreated animals 16 weeks after SNX. Glomerular volume was significantly (P < 0.05) less in 1,25(OH)2D3 treated SNX [10.1 +/- 1.75 in ethanol vs. 7.04 +/- 1.78 in 1,25(OH)2D3 treated SNX]. In parallel, there was significantly (P < 0.01) less glomerulosclerosis [glomerulosclerosis index 1.16 +/- 0.14 in the ethanol treated SNX vs. 0.80 +/- 0.16 in SNX treated with 1,25(OH)2D3] in the eight week experiment. Albuminuria was significantly (P < 0.01) lower in 1,25(OH)2D3 treated than in ethanol treated SNX (mean 0.785 mg/24 hr, range 0.43 to 1.80, vs. 3.75 mg/24 hr, 1.29 to 14.2). The morphological data were directionally analogous in a second 16 week experiment. Only slight changes of the vascular sclerosis index and tubulointerstitial index were seen in SNX and were not affected by 1,25(OH)2D3 further. To prove that the effect of 1,25(OH)2D3 was independent of PTH, parathyreoidectomized SNX rats without or with 1,25(OH)2D3 treatment were examined seven days post-SNX. PCNA staining showed suppression of cell proliferation. Furthermore, in situ hybridization for transforming growth factor-B (TGF-beta) showed less vascular and tubular expression in 1,25(OH)2D3 treated rats. We conclude that 1,25(OH)2D3 has antiproliferative actions during the compensatory growth of nephrons in response to subtotal nephrectomy. These effects are independent of PTH. The data document that 1,25(OH)2D3 reduces renal cell proliferation and glomerular growth as well as glomerulosclerosis and albuminuria as indicators of progressive glomerular damage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607202     DOI: 10.1046/j.1523-1755.1998.00951.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  70 in total

Review 1.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

2.  Estimated GFR, albuminuria, and complications of chronic kidney disease.

Authors:  Lesley A Inker; Josef Coresh; Andrew S Levey; Marcello Tonelli; Paul Muntner
Journal:  J Am Soc Nephrol       Date:  2011-09-30       Impact factor: 10.121

3.  Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate.

Authors:  Ian H de Boer; Ronit Katz; Michel Chonchol; Joachim H Ix; Mark J Sarnak; Michael G Shlipak; David S Siscovick; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-11       Impact factor: 8.237

4.  Therapeutic role and potential mechanisms of active Vitamin D in renal interstitial fibrosis.

Authors:  Xiaoyue Tan; Yingjian Li; Youhua Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-05       Impact factor: 4.292

5.  Vitamin D deficiency: consequence or cause of CKD?

Authors:  Ian H de Boer; Ravi Thadhani
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-17       Impact factor: 8.237

6.  25-hydroxyvitamin D levels, race, and the progression of kidney disease.

Authors:  Michal L Melamed; Brad Astor; Erin D Michos; Thomas H Hostetter; Neil R Powe; Paul Muntner
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

7.  Characterization of the renal phenotype in a mouse model of Marfan syndrome.

Authors:  Andrea Hartner; Timo Eifert; Christian S Haas; Cigdem Tuysuz; Karl F Hilgers; Dieter P Reinhardt; Kerstin Amann
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

8.  Vitamin D and kidney disease.

Authors:  Wisam Al-Badr; Kevin J Martin
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

9.  Vitamin D status and outcomes after renal transplantation.

Authors:  Frank Bienaimé; Delphine Girard; Dany Anglicheau; Guillaume Canaud; Jean Claude Souberbielle; Henri Kreis; Laure Hélène Noël; Gérard Friedlander; Caroline Elie; Christophe Legendre; Dominique Prié
Journal:  J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 10.121

10.  Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Authors:  Anthony A Portale; Myles S Wolf; Shari Messinger; Farzana Perwad; Harald Jüppner; Bradley A Warady; Susan L Furth; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-25       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.